Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 23, 2026.

Structures, functions and adaptations of the human LINE-1 ORF2 protein

Eric T. Baldwin, Trevor van Eeuwen, David Hoyos and 42 more

Nature · 2023

doi:10.1038/s41586-023-06947-z

Abstract

The LINE-1 (L1) retrotransposon is an ancient genetic parasite that has written around one-third of the human genome through a ‘copy and paste’ mechanism catalysed by its multifunctional enzyme, open reading frame 2 protein (ORF2p) 1 . ORF2p reverse transcriptase (RT) and endonuclease activities have been implicated in the pathophysiology of cancer 2,3 , autoimmunity 4,5 and ageing 6,7 , making ORF2p a potential therapeutic target. However, a lack of structural and mechanistic knowledge has hampered efforts to rationally exploit it. We report structures of the human ORF2p ‘core’ (residues 238–1061, including the RT domain) by X-ray crystallography and cryo-electron microscopy in several conformational states. Our analyses identified two previously undescribed folded domains, extensive contacts to RNA templates and associated adaptations that contribute to unique aspects of the L1 replication cycle. Computed integrative structural models of full-length ORF2p show a dynamic closed-ring conformation that appears to open during retrotransposition. We characterize ORF2p RT inhibition and reveal its underlying structural basis. Imaging and biochemistry show that non-canonical cytosolic ORF2p RT activity can produce RNA:DNA hybrids, activating innate immune signalling through cGAS/STING and resulting in interferon production 6–8 . In contrast to retroviral RTs, L1 RT is efficiently primed by short RNAs and hairpins, which probably explains cytosolic priming. Other biochemical activities including processivity, DNA-directed polymerization, non-templated base addition and template switching together allow us to propose a revised L1 insertion model. Finally, our evolutionary analysis demonstrates structural conservation between ORF2p and other RNA- and DNA-dependent polymerases. We therefore provide key mechanistic insights into L1 polymerization and insertion, shed light on the evolutionary history of L1 and enable rational drug development targeting L1.

Shown for reading. Its publisher allows quoting it, not republishing it.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 23, 2026. Paragraph numbers are ours, so an answer can point at one.

Main

Recent primate transposon evolution is dominated by RNA ‘copy and paste’ retrotransposons that insert RNA intermediates into the genome by encoded reverse transcriptase (RT) activity. These retrotransposons are divided into two classes: (1) endogenous retroviruses (ERVs), flanked by long terminal repeats (LTRs); and (2) the non-LTR retrotransposon long interspersed element-1 (LINE-1, L1). ERVs are no longer thought to be active in humans. By contrast, each person inherits about 100 polymorphic and fixed potentially active L1s, a small subset of the approximately half a million inactive L1 copies and fragments. LINEs have been coevolving with their hosts for 1–2 billion years, since the emergence of eukaryotes. Human L1 encodes two proteins, ORF1p and ORF2p, the latter having endonuclease (EN) and RT activities–, along with three other domains with unknown functions (Fig. 1a,b). ORF2p cotranslationally binds its encoding L1 RNA, a property termed ‘cis preference’–, forming a ribonucleoprotein (RNP) complex with many copies of ORF1 and host proteins,,– (Fig. 1b). New insertions begin with the target primed reverse transcription (TPRT) priming mechanism: an EN nick on the ‘bottom’ DNA strand liberates a DNA 3′-OH used to prime RT and generate an RNA:DNA hybrid intermediate–. The details of TPRT in L1, second strand synthesis and how the resulting intermediates are resolved remain unclear, although it is known that a subsequent staggered break in the second ‘top’ DNA strand results in a characteristic target site duplication of typically less than 20 base pairs (bp) flanking L1-mediated insertions,. Despite its cis preference, ORF2p also binds and inserts other RNAs, including messenger RNA sequences and short interspersed element RNAs such as Alu.

Derepressed L1 elements can contribute to the pathology of cancer, ageing, neurodegeneration and inflammation (mechanisms posited in Fig. 1b). Consistent with this, RT inhibitors have shown promising results in model systems–,, and in clinical studies of colorectal cancer and Aicardi–Goutières syndrome, a rare Mendelian interferonopathy characterized by accumulation of L1 intermediates,,. However, our knowledge of the mechanistic details of both L1 insertion and how L1 contributes to pathophysiology is limited. The best characterized L1 relatives are insect R2 LINE elements and bacterial group II mobile introns,, which lack the amino-terminal apurinic/apyrimidinic EN (APE)-like EN of ORF2p, and diverged from the human lineage around 700 million and 4 billion years ago, respectively. Both recognize and mobilize unique DNA and RNA sequences, limiting comparison with L1.

To address knowledge gaps in L1 biology and facilitate the potential for drug discovery, we have established systems to purify both full-length ORF2p and a minimal ‘core’, characterized ORF2p RT activity, and determined its structure using various modalities. Our investigation revealed (1) efficient RT priming by short RNAs and hairpins; (2) direct cytosolic synthesis of RNA:DNA hybrids that activate cGAS-STING, resulting in interferon production; (3) a series of conformational adaptations in the ‘right-handed’ fingers, palm and thumb RT fold that are likely to modulate biochemical activities required for the replication cycle of L1; (4) the presence of two previously undescribed domains in the RT core, which we name ‘tower’ and ‘wrist’; and (5) concerted dynamics of the N-terminal EN and carboxy-terminal domain (CTD). Informed by this structure, we elucidate the evolutionary relationships between conserved structural features in ORF2p. Our results shed light on previously enigmatic steps in the L1 replication cycle, its roles in pathophysiology and potential routes to therapeutics.

Purification of highly active ORF2p RT

Previous efforts to measure ORF2p enzymatic activity have been limited by an inability to purify more than trace amounts of ORF2p RT, with limited characterization of impure enzyme indicating that ORF2p may be able to perform DNA synthesis using RNA or DNA templates,,. Here, we optimized purification of the ORF2p core (residues 238–1061) to yield milligram quantities of more than 99% pure enzyme (Fig. 1c) that was monomeric (Extended Data Fig. 1a) and highly active against oligo(A) templates (Extended Data Fig. 1b), enabling structural and kinetic analyses, as well as single-base-resolution assays with various substrates and inhibitors.

A 2.1 Å crystal structure of the ORF2p core

To characterize domains of ORF2p of previously unknown function, understand how these domains interact during priming and reverse transcription, and elucidate the structural basis of differential RT inhibition as a basis for rational drug design, we solved the crystal structure of ORF2p core in an active configuration, using an AlphaFold model for molecular replacement (Extended Data Table 1 and Extended Data Fig. 1c). The structure represents a ternary complex with an incoming deoxythymidine triphosphate (dTTP) nucleotide and a template–primer heteroduplex containing a three-nucleotide (nt) 5′ overhang in the RNA template and 3′ dideoxy-terminated DNA primer. The complex crystallized in space group C2, with one monomer in the asymmetric unit. The structure (Fig. 1d) reveals the fingers, palm and thumb of a characteristic right-hand RT fold but also shows key differences compared with other RTs. Two folded domains which we name ‘wrist’ (863–1061) and ‘tower’ (240–440, Figs. 1d and 2, described below) are absent from other known structures of RT enzymes from viruses or mobile elements. All five domains make extensive contact with the bound nucleic acid (Supplementary Methods, Fig. 1d inset diagram and Extended Data Fig. 1e).

Five ORF2p core domains all bind nucleic acid

As in other RTs, the fingers, palm and thumb domains form a groove that cradles the RNA template–DNA primer heteroduplex. Nucleotide positions in the template and primer are numbered n−3 to n+10 relative to 5′, and n−1 is the templating ribonucleoside and incoming deoxyribonucleoside triphosphate (dNTP) (Fig. 1d, insets, and Extended Data Fig. 1e). We identify template contacts in both new domains: the tower contacts the 5′ RNA template at the n−3 base, and the wrist makes multiple contacts with the downstream region of the template (3′ end). The overall configuration of the active site and resultant catalytic mechanism are highly conserved throughout RTs and related polymerases,: in a region of the palm termed the N-site, the incoming dNTP base pairs with the n−1 base on the template and is poised for covalent linkage to the 3′ hydroxyl of the primer n+1 deoxyribose ring. The catalytic triad of aspartic acids (D600, D702, D703) resides at the active site and coordinates a Mg2+ ion and the dNTP; D702 and D703 form the base of the FADD loop (Fig. 1d, inset). The gatekeeping residue F605 has an aromatic side chain that selects against ribonucleotides with a 2′ hydroxyl, which probably explains the inability of ORF2p to function as an RNA-dependent RNA polymerase (RdRp); Extended Data Figs. 1d and 4c and Supplementary Fig. 3c). The 5′ upstream RNA template enters ORF2p above the fingertips, with eight residues contacting n−3, including hydrogen bonding between the base and an extended palm loop and the tower. The template next interacts with the R0 loop, which forms a ‘lid’ over the template RNA. This loop is a portion of the R0 region, also called the N-terminal extension (NTE)-0, which is found in non-LTR retrotransposons, the group IIC intron and HCV RdRp, but not in viral RTs, and has been demonstrated to be important for template jumping and/or switching activity, (‘Domain comparison of ORF2p and other RTs’). The downstream template makes extensive interactions continuing until the n+8 position with fingers, palm, wrist and thumb (Fig. 1, diagram). The DNA primer is contacted through the n+5 position, held upstream by the primer grip and downstream by the thumb with the helix clamp at its base.

Structure of the L1 wrist domain

The wrist domain (863–1061) has not been previously recognized, although experiments deleting large portions of the wrist and the subsequent CTD have shown that both domains are required for efficient retrotransposition. Scanning mutagenesis also has shown numerous wrist regions required for retrotransposition. The fold consists of 12 helices anchored to the RT through interactions with the thumb helices and palm through a helix at residues 573–581 and a short β turn at residues 688–695. Searches on similarity servers Dali and Foldseek show weak similarity to a sterile alpha motif-like domain, indicating possible roles in nucleic acid binding or protein–protein interactions. In the structure, the wrist makes numerous backbone contacts with the RNA template through n+4 to n+7, and trialanine mutants spanning these residues have resulted in reduced or no retrotransposition activity.

ORF2p cryo-electron microscopy structures in three states

We next measured the thermal stability of ORF2p in differential scanning fluorometry assays, in which heat-induced denaturation results in increasing exposure of the hydrophobic core of the protein and resultant binding and fluorescence of the SYPRO Orange dye. Apo ORF2p, lacking bound nucleic acid, was unstable, with a melting temperature (Tm) of 34.1 ± 0.4 °C. ORF2p was markedly stabilized by binding single-stranded RNA (ssRNA) (ΔTm = 14.4 ± 0.6 °C) and further stabilized by binding an RNA:DNA hybrid (Fig. 2a; ΔTm from ssRNA-bound = 2.7 ± 0.4 °C, ΔTm from apo = 16.1 ± 0.4 °C). To understand the structural changes resulting from binding of the primer and template, we used single-particle cryo-electron microscopy (cryo-EM; Extended Data Table 2 and Supplementary Figs. 1 and 2) to obtain reconstructions of ORF2p in three distinct states: in an active ternary complex with incoming dTTP and template–primer; bound to oligo-25(A) ssRNA; and in apo form (to 3.30, 3.66 and 4.06 Å resolution, respectively; Extended Data Fig. 2a). This is the first reported structure of an RT bound with ssRNA in the active site.

The density for the active ternary complex was complete and facilitated building of a structural model with clear density for the incoming dNTP, Mg2+ and template–primer (Fig. 2b, inset left). The cryo-EM-derived atomic model was predominantly indistinguishable from the crystal structure, with an overall root mean square deviation (RMSD) of 1.01 Å in tower–fingers–palm–thumb. There was apparent flexibility between the wrist and the rest of ORF2p, but the wrist fold itself was predominantly unchanged between the two structures (wrist backbone RMSD of 4.04 Å, aligned wrist RMSD = 1.01 Å, overall RMSD including wrist 3.68 Å; Extended Data Fig. 2b). Comparison of heteroduplex and ssRNA-bound states revealed distinct template paths (template RMSD of 3.76 Å; Fig. 2b, inset right) but overall maintenance of similar contacts through movement of flexible loops, notably in the palm and wrist domains. Intriguingly, although the structure was not as high resolution, the apo ORF2p was found in a ‘thumb up’ conformation, in which the template binding and active sites were accessible; by contrast, apo viral RTs assumed an inactive ‘thumb down’ conformation, in which the thumb occupied the nucleic-acid-binding site (Extended Data Fig. 2c,d). This ‘thumb up’ conformation, the instability of the apo protein and tight RNA binding are likely to contribute to the cis preference of L1.

Structure of the L1 tower domain

ORF2p contains an N-terminal APE-like EN and is the first such retrotransposon to be structurally characterized; other classes of non-LTR retrotransposons have C-terminal restriction-like ENs (RLE)–. The tower domain (239–440) corresponds to the region between the EN and RT domains and consists of four key components, (1) a baseplate (residues 254–300), (2) the protruding tower helices (residues 301–370), (3) the subsequent tower lock (residues 374–382) and (4) a PIP box helix (PCNA-interacting protein, residues 404–419), and encompasses regions previously termed ‘cryptic’ or ‘desert’,. Structure similarity searches did not show significant similarities to other proteins. The tower baseplate (Fig. 2c) was resolved to residue 304 in the crystal and 310 in our EM model. The tower and lock were anchored to RT at two points: (1) by the baseplate to fingers through mostly hydrophobic contacts, and (2) by PIP to the palm and fingers by a mix of hydrophobic and polar interactions. Mutation of key residues in the baseplate reduce retrotransposition, and PIP orchestrates an ORF2p–PCNA interaction that depends on EN and RT activities and is required for retrotransposition,,. AlphaFold2 modelling indicates that the intervening helices form an elongated hairpin-like tower, which seems to be flexible. Modelling using molecular dynamics simulations and AlphaFold indicated that the tower lock is consistent with orphan density above the n+4 base in low-pass filtered cryo-EM maps of ssRNA-bound ORF2p and may therefore fold down and ‘cap’ the RNA template (Extended Data Fig. 2d). A functionally similar tower lock was present in the smaller tower-like domain in R2, despite sequence divergence (see domain comparison below),. To test the importance of the unresolved tower and tower lock on RT activity, we purified ORF2p mutants that truncated the tower (Δ302–363) or tower and tower lock (Δ302–389), replacing them with short flexible linkers (Extended Data Fig. 3a,b). Both constructs were active similarly to the wild type in RT assays (Fig. 2d and Extended Data Fig. 3c,d), but trialanine mutagenesis has shown no retrotransposition with mutants in various regions of the tower and in the lock. Together, these data demonstrate that the ORF2p tower is important for L1 retrotransposition but not RT activity. They also indicate that ORF2p fragments consisting of portions of the tower base may be able to bind to the rest of ORF2p in trans, enabling ‘bipartile’ Alu retrotransposition.

ORF2p RT and polymerase activities

ORF2p can polymerize DNA on RNA or DNA templates (RT or pol activities) with approximately equal efficiency using either DNA or RNA primers. RNA priming of cDNA synthesis on an RNA template is less efficient but still occurs at a significant rate (Fig. 3a and Supplementary Fig. 3a,b). This reduced but significant level of L1 ORF2p RNA priming on RNA templates is in stark contrast with HIV-1 RT, for which only specialized RNA primers are used in initiation, at an efficiency reduced by orders of magnitude. L1 ORF2p RNA synthesis (RdRp activity) was strongly selected against, with minimal detectable activity (Extended Data Fig. 4c and Supplementary Fig. 3c). In single-nucleotide additions with long 20 nt primers, ORF2p had no apparent preference for an RNA or DNA template. HIV-1 RT and human ERV K (HERV-K) RT also accept both templates and have roughly ten-fold and two-fold higher efficiency of single nucleotide incorporations than L1 ORF2p, respectively. By contrast, whereas ORF2p efficiently extended 5 nt DNA primers on DNA or RNA templates, HIV-1 RT had markedly reduced efficiency with 6 nt primers in RT reactions, was incapable of reverse transcribing a 5 nt primer, and did not extend primers 5–10 nt long on DNA templates (Extended Data Figs. 4a,b and 5a,b). ORF2p was highly processive and unaffected by a heparin competitor, whereas HIV-1 RT was significantly less processive at baseline and did not produce full-length template with a heparin competitor in any condition (Extended Data Fig. 5c).

ORF2p also consistently produced larger products of two types, which increased with both longer reaction times and higher concentrations of reaction components: (1) non-templated addition (NTA, or 3′ tailing), in which single bases are added beyond the 5′ end of the template; and (2) template jumping or template switching products, in which polymerization of the same cDNA strand (copy of template1) continues on a new incoming template molecule (template2) that is accepted and copied, making a concatemer (copy of template1 + copy of template2 (Supplementary Fig. 4). No NTA or template jumping activities of ORF2p were detectable with HIV-1 RT (Extended Data Fig. 5b). These activities have been well characterized in other non-LTR transposons and are thought to be important for completion of an insertion (‘Discussion’) but have not previously been shown for ORF2p. NTA activity mechanistically explains previously reported ‘5′ extra nucleotides’ or ‘microhomologies’ observed in naturally occurring and engineered L1 insertions,.

ORF2p is known to tolerate some terminal mismatches in priming in crude RNP complex preparations,. In assays with an RNA template terminating in A, ORF2p showed little discrimination against terminal mismatches, with the exception of A:G, which retained some detectable activity. These results are similar to those of previous studies using RNP preparations, in which the predominant template was presumed to be the poly(A) tail, and the similarity between the two results is evidence that most ORF2p in L1 RNP preparations rests on the poly(A) tail–. C:U and T:U internal mismatches at the second-to-last position are also tolerated, along with a UA:TC double mismatch, to a lesser extent. Overall, ORF2p is similarly active to HIV-1 RT but tolerates more mismatches (A:A and A:G mismatches are not tolerated by HIV-1 RT; Extended Data Fig. 4d). This reduced specificity may facilitate priming against diverse cellular sequences.

Requirements for ORF2p priming

ORF2p efficiently extends DNA primers as short as 5 nt on RNA or DNA templates, with slightly lower efficiency at 5 and 6 nt than at 7–20 nt (Fig. 3c and Extended Data Figs. 4b and 5b). This is consistent with requirements of 4–6 bp annealing seen in RNP preparation assays, in which the predominant template is assumed to be the poly(A) tail, and with the five primer bases that contact ORF2p (Fig. 1d). These priming results led us to investigate whether L1 ORF2p might directly accept and extend short RNA hairpin substrates. ORF2p efficiently extended a previously published 29 nt RNA hairpin containing a 7 nt duplex (Fig. 3d) and a similar hairpin derived from the substrates tested above (Supplementary Fig. 5), even at the lowest dNTP concentration tested (0.1 µM), which was at least ten-fold lower than the physiologic dNTP concentration. This activity was barely detectable with HIV-1 RT at 100 µM, a difference in activity of at least four orders of magnitude; by contrast, the two enzyme preparations were similarly active in RT reactions (Fig. 3d and Extended Data Figs. 4d and 5b). As recent studies report cytosolic synthesis of Alu cDNA and indicate possible priming against the oligo(A) tail by the pol-III terminal U-tract, we tested an Alu-derived sequence and found that this hairpin was also efficiently extended by ORF2p (Fig. 3e and Supplementary Fig. 5). In all cases, RNA synthesis was strongly selected against, although more activity was consistently seen at 1 mM NTPs; this concentration is likely to be supraphysiologic for all but ATP. Together, these results demonstrate that ORF2p can synthesize cDNA primed only by short RNA sequences and hairpins at physiologic concentrations of dNTPs, providing a potential mechanistic basis for its cytosolic RT activity,,.

ORF2p synthesizes cDNA in the cytosol

Various cytosolic single-stranded DNAs (ssDNAs), double-stranded nucleic acids and Alu cDNAs have been identified in senescent cells,, retinal cells and neural progenitors, along with L1 ORF1 protein. Although RT inhibitors often reduce or ablate cDNA levels, their origin has remained uncertain. We transfected HeLa and U2-OS cells with plasmids expressing L1 and found robust cytosolic RNA:DNA hybrids in transfected cells that colocalized with both L1 proteins, depended on RT activity, and were unaffected by loss of EN activity. Their formation was inhibited by 50 µM d4T treatment (Fig. 3f and Extended Data Fig. 6a–c). Hybrids were seen using synthetic ORFeus-Hs L1 and native L1RP sequences and with two different detection reagents: S9.6, a well-established monoclonal antibody known also to bind dsRNA under some conditions, and purified catalytically inactive human RNase H1 (dRNH1), which has recently been reported to be more specific for hybrids in imaging experiments. Hybrids were also detectable in some cells in smaller punctae when ORF2p was expressed in the absence of ORF1 (Fig. 3f and Extended Data Fig. 6a–c). As EN-independent retrotransposition occurs at levels at least 100-fold lower than wild type, these results rule out a nuclear origin for these cytosolic hybrids and demonstrate that L1 can directly synthesize RNA:DNA hybrids in the cytosol.

Synthesized cDNAs activate cGAS/STING

To investigate the consequences of cytosolic L1 RT activity, we used a secreted luciferase interferon reporter in THP1 cells, a leukaemia cell line with monocytic differentiation. Treating THP1 cells with 1 µM decitabine derepresses L1 expression by preventing DNA methylation during replication and results in interferon production,, (Fig. 3g). Knockout of TREX1 (three-prime repair exonuclease 1), a nuclease that is mutated in Aicardi–Goutières syndrome and systemic lupus erythematous and that has been shown to degrade cytosolic L1 DNA,,, increased both baseline and decitabine-induced interferon levels (Fig. 3g). Both baseline and decitabine-induced interferon levels were reduced by treatment with a cGAS inhibitor (10 µM G140) or RT inhibitor (RTI; 50 µM d4T) (Fig. 3g and Extended Data Fig. 6d,e). As d4T potency was modest in this assay, we tested whether triphosphorylation of d4T was limiting inhibition by synthesizing a POC prodrug of d4T (POC d4T (d4T bis(isopropoxycarbonyloxymethyl)phosphate; Supplementary Fig. 6b)). POC d4T was approximately 30-fold more potent than d4T in suppressing interferon secretion, which provides compelling evidence that d4T triphosphate is the active form that inhibits ORF2p (Fig. 3g and Extended Data Fig. 6e). Together, these results demonstrate that cytosolic cDNA synthesis by L1 results in interferon production through the cGAS/STING pathway.

In vitro inhibition of ORF2p

A critical path towards treating diseases associated with RT activity, such as HIV and HBV infections, is the use of RTIs. Given the emerging role of L1 in disease, we sought to determine whether current RTIs had activity against ORF2p. Titrating nucleoside triphosphate (NTP) forms of nucleoside RTIs (NRTIs) into gel-based L1 RT assays showed that 3TC (lamivudine, Extended Data Fig. 7a) and carbovir (the active metabolite of abacavir) were modest ORF2p inhibitors (half-maximal inhibitory concentration (IC50) 5–7 µM), whereas d4T (stavudine) and entecavir were more potent (IC50 0.4–0.6 µM, Extended Data Fig. 7a). To enable robust high-throughput inhibition analysis, we developed homogeneous time-resolved fluorescence assays for ORF2p RT. NRTI NTPs all inhibited ORF2p to varying extents, with thymidine analogues dideoxythymidine (ddT) and d4T the most potent (IC50 < 10 nM), followed by AZT and 3TC as modest inhibitors under these conditions (IC50 200–750 nM) (Fig. 4a and Extended Data Fig. 7b,c). By contrast, none of the six tested allosteric HIV-1 non-nucleoside RTIs (NNRTIs) inhibited ORF2p; notably, even 1 mM nevirapine showed no inhibition (Fig. 4a, Extended Data Fig. 7c and Supplementary Fig. 6a,b). Using a stable dual luciferase retrotransposition reporter system in HeLa cells, we confirmed previously published modest inhibition of L1 by d4T, 3TC, FTC (emtricitabine), AZT, tenofovir and GBS-149 (IC50 1–5 µM) (Extended Data Fig. 7d). GBS-149 potency was not significantly different from that of related 3TC and FTC; the HCV inhibitor sofosbuvir did not inhibit L1 at up to 30 µM (Extended Data Fig. 7d). Differences between the in vitro and cell-based assays may be attributable to differential triphosphorylation of NRTIs.

Structural basis of inhibition of ORF2p

Potency against ORF2p varied almost 200-fold between NRTIs tested, and AZT and 3TC were not potent inhibitors (Fig. 4a). In HIV-1, resistance to 3TC can come from M184 mutations in RT (YMDD to YVDD/YIDD), which cause a steric clash with the oxathiolane ring. HIV-1 mutants to Ala (YADD, like FADD in ORF2p) have been studied with respect to 3TC potency, demonstrating that van der Waals interactions between M184 and the 3TC oxathiolane ring are stabilizing; these interactions are not present with the smaller A701 (FADD) in ORF2p, and this difference may explain the relatively lower potency of 3TC against L1 ORF2p RT. Modelling the related 3TT-TP analogue into the active site of L1 using the cocrystal structure of dTTP confirmed the proximity of M701 to the oxathiolane ring, whereas the A701 in wild-type L1 was further away. Further supporting this mode of inhibition, 3TC was approximately 15-fold more potent in inhibiting A701M mutant full-length ORF2p (FMDD) than wild type (FADD, Fig. 4b and Extended Data Fig. 7e). On the basis of these results, HIV-1 inhibition and analyses of HERV-K, we conclude that 3TC and related FTC and GBS-149 are unlikely to be selective for L1 ORF2p.

To understand the structural basis underlying differences between AZT and more potent thymidine analogues, we modelled the triphosphates of thymidine-based NRTIs into the ORF2p ternary crystal structure containing dTTP in the N-site. As expected, ddTTP and d4T-TP did not show any clashes with the protein, as they closely resemble the shape of dTTP. However, the AZT-TP model showed a clash of the middle nitrogen of the 3′-azido group with amide hydrogen of F605 (distance 2.03 Å, Fig. 4c), which was not relieved by energy minimization. This clash was not observed in the crystal structure of AZT-TP bound to HIV-1 RT (respective distance 2.28 Å, Fig. 4c). The inability to remove the clash in ORF2p may be explained by a difference in conformational flexibility of the region around the 3′-azido group (residues 602–607 in ORF2p and 112–117 in HIV-1 RT). In ORF2p, this segment contains two internal salt bridges that are absent from HIV-1 RT and has lower average backbone B factors than HIV-1 with respect to the complete dNTP site (defined as all residues within 6 Å of dTTP; site versus region in ORF2p, 43.4 versus 48.1; HIV-1 RT, 114.3 versus 110.7). Calculations on the basis of free energy perturbation simulations of the relative ORF2p binding of these nucleotides showed an insignificant difference in relative binding free energy (ΔG) between ddTTP and d4T, but a large positive difference between these and AZT (Supplementary Fig. 6c), consistent with the greater than 20-fold change in ORF2p inhibitory activity of AZT compared with ddTTP and d4T (Fig. 4a).

As inhibition of telomerase RT (TERT) would be a potential source of toxicity in a therapy, we investigated the relative selectivity of NRTI triphosphates for L1 versus TERT, testing the panel of NRTI triphosphates in a biochemical TERT assay. The tested compounds were generally around 1,000-fold less potent inhibitors of TERT than L1 RT, with IC50 in the mid-micromolar range (for example, the IC50 of d4T-TP was 9 nM versus ORF2p and 15 µM versus TERT; Supplementary Fig. 7a); this result was in line with expectations, because these drugs are all tolerated therapeutically in patients. The structures of the active sites of the two enzymes explain these stark differences, with a more hydrophobic environment in the ORF2p active site (Supplementary Fig. 7b,c). NRTIs designed for HCV RdRp are also unlikely to inhibit L1 as drugs of this class, like sofosbuvir, contain 2′ modifications mimicking the 2′-OH of an incoming ribonucleoside triphosphate. This was first confirmed by modelling of sofosbuvir into the ORF2p active site, which revealed a clash between the sofosbuvir 2′ F and the gatekeeping residue F605; this was further confirmed in cell-based L1 assays, which showed no inhibition by sofosbuvir (Extended Data Fig. 7d and Supplementary Fig. 7d). Together, these results demonstrate that the ORF2p crystal structure provides a useful starting point for structure-based design of new ORF2p-specific NRTIs.

NRTIs act at the RT active site and are known to inhibit ORF2p with varying potency, whereas HIV-1 NNRTIs bind to an induced allosteric site in the palm between the primer grip, the β-sheet containing the YMDD loop and the 94–102 segment; this pocket is absent from HBV, HIV-2 and HERV-K. HIV-1 NNRTIs do not inhibit ORF2p (Fig. 4a and Extended Data Fig. 7c,d), and structural and sequence differences between the HIV-1 NNRTI pocket and the equivalent region in ORF2p explain this lack of inhibition (Fig. 4d). As HIV-1 RT undergoes a conformational change when NNRTIs bind, the HIV-1 RT structure in the absence of NNRTI was compared with the ORF2p crystal structure. The most striking difference was replacement of the 94–102 segment of HIV-1 RT with a longer α-helix formed by residues 572–588 in ORF2p, making none of these positions structurally equivalent. In addition, residues Y181 and Y188, which have been implicated in aromatic ring stacking with nevirapine and other NNRTIs, were replaced with S698 and I705, respectively, and the small residue G190 in HIV-1 RT was replaced with bulky Y707 in ORF2p. These differences, taken together, explain why ORF2p does not form a pocket that binds HIV-1 NNRTIs.

Structure of full-length ORF2p

Purified full-length ORF2p was similarly active to the ORF2p core in single-nucleotide-resolution RT assays and was similarly inhibited by 3TC (Fig. 4e, Extended Data Fig. 7f and Supplementary Fig. 8a–c), indicating that EN and CTD may not directly modulate RT activity. Monodisperse full-length ORF2p, bound to the same short RNA17–DNA14 hybrid used above for cryo-EM of the ORF2p core, was analysed by negative stain transmission electron microscopy and found to be monomeric and probably flexible, with two-dimensional classes indicating multiple conformations (Fig. 4f, raw contour, and Supplementary Figs. 9–10). To elucidate the conformational landscape of ORF2p, we used cryo-EM maps, cross-linking mass spectrometry, AlphaFold2 and molecular dynamics simulations to generate an ensemble of conformational states using the Integrative Modeling Platform (Supplementary Figs. 8d,e, 9 and 10 and Supplementary Tables 1 and 2). Informed by AlphaFold2 and molecular dynamics simulations, we first segmented the EN, tower and CTD into 15 rigid bodies connected by 14 flexible linkers and computed an ensemble of integrative models satisfying the input data (Fig. 4g; conformational heterogeneity and model uncertainty is represented as localization densities). The ensemble was then validated by matching computed two-dimensional model projections to negative stain two-dimensional class averages: each class average was assigned a best-matching model and each matched model fit the data better than the parental AlphaFold model (Fig. 4f and Supplementary Fig. 10). Structural clustering of these best-matching models indicated two distinct groups (Fig. 4g and Supplementary Fig. 10), which we named ORF2p open and closed-ring states, that were characterized by unique positions of the EN and tower. Closure of the ring entailed an approximately 48 Å movement of the tower domain (measured from the top of the tower), hinging at the baseplate and bringing it adjacent to the CTD. To test potential roles of these states, we repeated the negative stain EM with ORF2p bound instead to a 376 nt RNA derived from the 3′ end of L1RP with a 14 A tail. Many classes overlapped, but there was also a significantly increased number of closed-ring states and a reduction in open states (Supplementary Fig. 10b–d). We interpret these differences to mean that the closed state may represent a predominant conformation when ORF2p is bound to messenger RNA, whereas the open state may be involved in retrotransposition.

Domain comparison of ORF2p and other RTs

To better understand specific adaptations of ORF2p, we compared it with diverse structurally characterized RTs: the R2 LINE element from the silk moth Bombyx mori (R2Bm), the distantly related mobile group IIC intron RT from Geobacillus stearothermophilus (GsI-IIC), the RT from LTR element HERV-K and HIV-1 RT (Extended Data Fig. 8a). The structure of the group IIC intron was chosen over the evolutionarily closer group IIB intron because it represents the same active form with substrate in the active site and is higher resolution, although members of the IIB family were included in the wider evolutionary analysis (see below). ORF2p is larger than the other enzymes, with limited similarity outside the conserved right-hand fingers–palm–thumb subdomains in RTs. Structural alignment of all five enzymes by palm superposition highlighted conserved RT sequence blocks and showed that ORF2p had insertions in fingers (motifs 0, 2a) and palm (motif 3a, 6a) and permutation of the thumb helices compared with both HIV-1 and HERV-K.

Viral and LTR transposon RTs, represented by HIV-1 and HERV-K, are distinct from the non-LTR RTs in that they encode their own RNase H, located C-terminally, and GsI-IIC has a DNA-binding D domain in this position (Extended Data Fig. 8c,d and Supplementary Fig. 11). Other than GsI-IIC D, these CTDs all stabilize the polymerase complex by coordinating downstream nucleic acids but do so in distinct ways. The ORF2p wrist binds the template close to the active site; the connection and RNase H domains of viral/LTR elements bind distally; and, although the linker of R2Bm makes limited and distinct nucleic acid contacts, most of its function seems to be coordination of the activity of the C-terminal RLE domain,. In R2Bm, RLE cuts ssDNA, which in the context of initiation is melted from the dsDNA target by the adjacent C-terminal CCHC zinc finger (ZnF),,. The ORF2p CTD is required for retrotransposition, and has a similarly positioned CCHC motif (Extended Data Fig. 9 and Supplementary Fig. 11) that may also melt target DNA and/or bind single-stranded nucleic acid, but its function remains unclear.

In comparison with R2Bm, the ORF2p domain topology is reversed: ORF2p apurinic/apyrimidinic endonuclease (APE)-like EN is located N-terminally and cuts dsDNA rather than ssDNA,,,. Structurally, ORF2p EN sits on the opposite wall of the polymerase groove to R2Bm RLE, atop fingers rather than thumb (Extended Data Fig. 9 and Supplementary Fig. 11). This seems to position the target DNA in reverse orientation to the active site for the two enzymes, although other orientations are possible (Extended Data Fig. 9). The tower of ORF2p seems to play a part in dynamic positioning of the EN. A smaller domain that we term ‘tower-like’ is present in R2 (residues 305–374); this region was previously annotated as NTE-1 and contains the tower lock as well as helices analogous to ORF2p PIP that anchor the tower lock to fingers and palm. However, the PIP box, tower and tower baseplate are not present in R2. R2Bm also has two N-terminal domains, Myb and N-ZnF, that recognize specific ribosomal DNA sequences unique to the element, reflecting the extremely high sequence specificity of R2 for a single site in the ribosomal DNA.

Structural adaptations of ORF2p RT

There are numerous contrasting features of the N-terminal regions of the four RT families (Extended Data Fig. 8b). Viral and LTR RTs have an α-helix posterior to the fingertips, which is absent from the group II intron RT but occupied by the tower-like helix of R2Bm and the PIP helix in ORF2p. The fingertips of all four representative RTs are similar in that they provide a hydrophobic surface for sliding the template bases (notably I515, I517 and I533 in ORF2p), but ORF2p and R2Bm both have a distinctive insertion in the fingertips loop. The upstream template path differs significantly in all four enzymes: in viral and LTR RTs, the 5′ template is pushed away from the fingertips by π-stacking with a characteristic tryptophan (W38 HERV-K, W24 HIV-1), whereas the non-LTR transposons and group II intron have a groove formed by the conserved R0 region with a loop that forms a lid for the template. Here, ORF2p is also distinct: the fingertips for group II intron and R2Bm have an arginine (R63 and R446, respectively) that forms a salt bridge with the n−2 phosphate, pushing the n−3 base away from the posterior side of the fingertips, whereas the analogous residue in ORF2p (T638) is significantly smaller and allows the n−3 base to fold into a hydrophobic pocket created by a loop from the palm anchored by I642. The result of this is an apparently different entry path of the template RNA. The R0 region also differs significantly between ORF2p and the group II intron and R2Bm: the R0 loop in ORF2p is the longest of the three and makes no primer contacts; by contrast, the group II intron and R2Bm both contact the n+6 primer backbone.

In these RT families, the proximal primer is anchored by a conserved primer grip in the palm, which contains a characteristic hydrophobic motif helix clamp (Extended Data Fig. 8c). C-terminal to the primer grip is the thumb domain, a parallel three-helix bundle that occupies the minor groove of the template–primer heteroduplex and makes extensive primer contacts. The thumb in LTR RTs is permuted relative to the other families: the second helix of ORF2p, R2Bm, and the group II intron is functionally analogous to the first α-helix in viral and LTR RTs and contains the helix clamp subdomain at its base (Extended Data Fig. 8c). The helix clamp proline in non-LTR RTs (P819 in ORF2p) assumes a similar function to the glycine in LTR RTs and the group II intron, allowing proximity to the minor groove, and the subsequent aromatic residue (Y823 in ORF2p) forms π-interactions with the primer n+2 or n+3 nucleotide backbone. The wrist of ORF2p makes more extensive contacts with the downstream template than either the group II intron D domain or the R2Bm linker.

Structural insight into L1 evolution

L1 dates to at least the Precambrian era; on the basis of limited sequence similarity, it is speculated to have a putative common ancestor with bacterial mobile group II introns and has no clear evolutionary ancestor among extant viruses. We therefore sought to use protein structure to shed light on the conserved features and evolutionary origin of ORF2p that cannot be identified by sequence alignment alone. We used multiple sequence/structural alignments and AlphaFold2 predictions to examine conservation of the human ORF2p structure relative to 57 other L1 ORF2p sequences from vertebrates and plants. By computing and plotting the residue-level diversity of the aligned ORF2ps as the Shannon entropy (Fig. 5a and Supplementary Methods), we found high concordance between the two multiple alignment strategies (sequence versus structural) in the RT domain (fingers–palm–thumb, Supplementary Fig. 12a). Despite relatively lower sequence conservation in regions of the tower, wrist and CTD domains, the structure was conserved, indicating that domain topology may be more important than the sequence of these domains for L1 function. Leveraging data from a published trialanine mutagenesis library of 417 consecutive AAA ORF2p mutants, in which residual function of mutants was compared with that of the wild type (100%), we found that structural entropy was significantly correlated with residues dispensable for retrotransposition activity (Fig. 5b,c and Supplementary Fig. 12a). As most mutations resulted in reduced function, these results together indicate that optimization of retrotransposition is a main evolutionary driving force.

We next compared ORF2p and other proteins with the intention of identifying shared structural features and inferring evolutionary relationships. First, we manually curated a set of 50 experimental protein structures that represented main families: RTs, RdRps, DdDps (DNA-dependent DNA polymerases) and DdDps/RdRps, as well as ‘negative controls’ that should have little resemblance to the other proteins (Supplementary Table 3). We then sought to represent structural similarity in a manner that would faithfully account for differences in protein length, account for inherent alignment quantity/quality trade-offs, and address a limitation of other methods, such as RMSD, in which different relative orientations of otherwise identical domains result in poor scores. We developed a new information-theoretic algorithm, named ‘Plexy’, which represents a high-quality alignment as one that reduces the structural perplexity between their coordinates (Supplementary Methods). The smaller this value, the more likely it is that one can ‘guess’ the coordinates of one structure knowing the coordinates of the other. Plotting structural perplexity from ORF2p RT for this set (Fig. 5d and Supplementary Figs. 12b,c and 13) showed that it recapitulates close relationships between ORF2p, R2Bm and group II introns, and that ‘negative control’ proteins have extremely high perplexities from ORF2p. To better understand relationships between full-length ORF2p and other proteins, we computed the pairwise structural distances across all pairs of proteins and normalized them with respect to the size of the two proteins and their alignment, anchoring the plot on the ORF2p crystal structure (Supplementary Methods, Fig. 5e). Across both datasets, proteins in the same functional class typically clustered together in an unsupervised manner, with R2Bm and group II introns again closest to ORF2p. Group IIB introns are thought to be evolutionarily closer to L1 than group IIC, but intriguingly both have similar perplexities from ORF2p with subtle differences in subdomains, highlighting structural conservation (Supplementary Fig. 13). Domesticated cellular RTs were next closest to ORF2p RT, but normalized distances between full-length ORF2p and Prp8 and TERT were larger owing to the incorporation of unrelated structural elements (Supplementary Fig. 12b). Viral RdRps such as HCV and influenza B have remarkable similarity to ORF2p RT; non-LTR and viral RTs are more distant. Notably, the inactive p51 HIV-1/2 RT subunit was predicted to be far more distant to ORF2p than the active p66 HIV-1/2 RT, despite identical amino acid sequence (up to a deletion). Therefore, this analytical framework quantifies conformational similarity in a manner that is sensitive to function.

Discussion

Our integrated analyses reveal the inner workings of the molecular machine that has written nearly half of the human genome. Understanding L1 structure and function is important both in evolution and, increasingly, in human disease. Accumulating evidence links L1 activity and the host response to common pathologies including cancer, ageing, neurodegeneration and autoimmunity–,,. Our biochemical, structural and evolutionary analyses show that ORF2p contains a highly active polymerase that is uniquely adapted for its parasitic replication cycle, with both conserved and new structural features that preserve optimal retrotransposition throughout evolution. Together, these data provide insights into two key underlying mechanisms through which L1 may cause disease: (1) nuclear insertional mutagenesis and resultant genomic havoc, and (2) cytosolic sensing of the products of ORF2p reverse transcription.

Although nuclear L1 activity has been correlated with DNA damage and structural genomic rearrangements,,,, a mechanistic understanding of L1 insertion has been elusive. The insertion process can be understood as two half reactions: first and second strand synthesis. Second strand synthesis has been challenging to study, and it was unclear whether it is performed by L1 or the host. Our data demonstrate that ORF2p is competent to perform all enzymatic steps required to prime and execute both first and second strand syntheses: it effectively synthesizes DNA with short RNA or DNA primers on both RNA and DNA templates (Fig. 3, Extended Data Figs. 4 and 5 and Supplementary Figs. 3–5). Interpreting our results in the context of high-quality biochemical data from decades of studying the R2 LINEs in insects,,, provides us with the opportunity to update the L1 insertion model (Fig. 6). The mechanism describes a canonical insertion that is intentionally simplified and omits numerous supportive and repressive host proteins, including topoisomerase TOP1, PARP1, purine-rich element binding proteins, the Fanconi pathway (including BRCA1) and p53 (refs.,–). Furthermore, alternative pathways as such host-catalysed second strand synthesis may occur in different contexts or following ORF2p failure, and the host may combat insertion by, for example, cleaving intermediates.

Our data also shed light on other areas of the canonical L1 replication cycle. ORF2p cis RNA binding is thought to occur at the ribosome,. Newly translated apo ORF2p is unstable until RNA is bound, and it assumes a ‘thumb up’ conformation competent to tightly bind RNA; we speculate that the initial RNA binding probably occurs cotranslationally, potentially before the CTD has even been translated. PCNA binding, which is required for retrotransposition and recruits RNase H2 to allow second strand cleavage, does not seem to be occluded in any identified state; this, together with EN and RT dependence,, indicates that PCNA may be recruited to ORF2p by the developing genomic lesion. Most new LINE insertions are heavily 5′ truncated; often they comprise only a few hundred base pairs, but the reasons are not well understood. ORF2p is efficient and highly processive, consistent with previous observations,, adding support to the idea that host cleavage of the L1 RNA or intermediates is more likely to cause 5′ truncation than inefficiency of the polymerase. Nuclear ORF1p levels are limited,, and bound ORF1p chaperones would be displaced from L1 RNA during RT, potentially leaving the large single-stranded cDNA loop intermediate unprotected (steps 3–7, Fig. 6). This could represent both a unique vulnerability and a potential nidus for translocations,,, given its homology to much of the genome.

Cytosolic double-stranded nucleic acids, viral mimicry and resultant interferon signalling are known to contribute to pathology in several contexts, and NRTIs have been shown to limit the production of interferon and of these nucleic acids,, but their origin has remained controversial. First, our data show that ORF2p can use RNA primers and short RNA hairpins to initiate RT reactions; an Alu-like sequence is readily extended, and uridylation of the L1 RNA might convert it into a similar substrate as well. RNA priming of ORF2p RT in the cytoplasm can parsimoniously explain the origin of these nucleic acids. We also show that DNA primers as short as 5 nt can prime L1; it is possible that shorter primers are also tolerated. Second, we demonstrate that L1 can directly synthesize RNA:DNA hybrids in the cytosol; these are RT-dependent but EN-independent, ruling out a nuclear origin in this system. Third, we show that L1 synthesized cDNAs activate cGAS/STING, resulting in interferon production. Our observations further demonstrate the potentially critical role of L1 and its RT products in viral mimicry,, as inferred from genome and cancer evolution,. Moreover, our robust inhibitor data provide a framework for evaluating the involvement of L1 in these phenotypes and for targeting this in the future. In summary, our structural elucidation of ORF2p will facilitate rational design of new therapeutics and lays the groundwork for future studies needed to dissect and improve our understanding of the insertion mechanism of L1, its evolution and its roles in disease.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at 10.1038/s41586-023-06947-z.

References 77

  1. 1.

    Kazazian HH, Moran JV. Mobile DNA in health and disease. N. Engl. J. Med. 2017;377:361-370.

    Not in our library10.1056/nejmra1510092

  2. 2.
  3. 3.

    Taylor, M. S. et al. Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker. Cancer Discov.13, 2532–2547 (2023).

    Not in our library10.1158/2159-8290.cd-23-0313

  4. 4.

    Rice GI, et al. Reverse-transcriptase inhibitors in the Aicardi-Goutieres syndrome. N. Engl. J. Med. 2018;379:2275-2277.

    Not in our library10.1056/nejmc1810983

  5. 5.

    Carter V, et al. High prevalence and disease correlation of autoantibodies against p40 encoded by long interspersed nuclear elements in systemic lupus erythematosus. Arthritis Rheumatol. 2020;72:89-99.

    Not in our library10.1002/art.41054

  6. 6.

    De Cecco M, et al. L1 drives IFN in senescent cells and promotes age-associated inflammation. Nature. 2019;566:73-78.

    Not in our library10.1038/s41586-018-0784-9

  7. 7.

    Simon M, et al. LINE1 derepression in aged wild-type and SIRT6-deficient mice drives inflammation. Cell Metab. 2019;29:871-885.e875.

    Not in our library10.1016/j.cmet.2019.02.014

  8. 8.

    Ardeljan D, et al. Cell fitness screens reveal a conflict between LINE-1 retrotransposition and DNA replication. Nat. Struct. Mol. Biol. 2020;27:168-178.

    Not in our library10.1038/s41594-020-0372-1

  9. 9.

    Boeke JD, Garfinkel DJ, Styles CA, Fink GR. Ty elements transpose through an RNA intermediate. Cell. 1985;40:491-500.

    Not in our library10.1016/0092-8674(85)90197-7

  10. 10.

    Hohjoh H, Singer MF. Cytoplasmic ribonucleoprotein complexes containing human LINE-1 protein and RNA. EMBO J. 1996;15:630-639.

    Not in our library10.1002/j.1460-2075.1996.tb00395.x

  11. 11.

    Mathias SL, Scott AF, Kazazian HH, Boeke JD, Gabriel A. Reverse transcriptase encoded by a human transposable element. Science. 1991;254:1808-1810.

    Not in our library10.1126/science.1722352

  12. 12.

    Feng Q, Moran JV, Kazazian HH, Boeke JD. Human L1 retrotransposon encodes a conserved endonuclease required for retrotransposition. Cell. 1996;87:905-916.

    Not in our library10.1016/s0092-8674(00)81997-2

  13. 13.

    Weichenrieder O, Repanas K, Perrakis A. Crystal structure of the targeting endonuclease of the human LINE-1 retrotransposon. Structure. 2004;12:975-986.

    Not in our library10.1016/j.str.2004.04.011

  14. 14.

    Wei W, et al. Human L1 retrotransposition: cis preference versus trans complementation. Mol. Cell. Biol. 2001;21:1429-1439.

    Not in our library10.1128/mcb.21.4.1429-1439.2001

  15. 15.

    Kulpa DA, Moran JV. Cis-preferential LINE-1 reverse transcriptase activity in ribonucleoprotein particles. Nat. Struct. Mol. Biol. 2006;13:655-660.

    Not in our library10.1038/nsmb1107

  16. 16.

    Monot C, et al. The specificity and flexibility of l1 reverse transcription priming at imperfect T-tracts. PLoS Genet. 2013;9:e1003499.

    Not in our library10.1371/journal.pgen.1003499

  17. 17.

    Taylor MS, et al. Affinity proteomics reveals human host factors implicated in discrete stages of LINE-1 retrotransposition. Cell. 2013;155:1034-1048.

    Not in our library10.1016/j.cell.2013.10.021

  18. 18.

    Taylor MS, et al. Dissection of affinity captured LINE-1 macromolecular complexes. eLife. 2018;7:e30094.

    Not in our library10.7554/elife.30094

  19. 19.

    Liu N, et al. Selective silencing of euchromatic L1s revealed by genome-wide screens for L1 regulators. Nature. 2018;553:228-232.

    Not in our library10.1038/nature25179

  20. 20.

    Cost GJ, Feng Q, Jacquier A, Boeke JD. Human L1 element target-primed reverse transcription in vitro. EMBO J. 2002;21:5899-5910.

    Not in our library10.1093/emboj/cdf592

  21. 21.

    Luan DD, Korman MH, Jakubczak JL, Eickbush TH. Reverse transcription of R2Bm RNA is primed by a nick at the chromosomal target site: a mechanism for non-LTR retrotransposition. Cell. 1993;72:595-605.

    Not in our library10.1016/0092-8674(93)90078-5

  22. 22.

    Wilkinson, M. E., Frangieh, C. J., Macrae, R. K. & Zhang, F. Structure of the R2 non-LTR retrotransposon initiating target-primed reverse transcription. Science380, 301–308 (2023).

    Not in our library10.1126/science.adg7883

  23. 23.

    Deng P, et al. Structural RNA components supervise the sequential DNA cleavage in R2 retrotransposon. Cell. 2023;186:2865-2879.e2820.

    Not in our library10.1016/j.cell.2023.05.032

  24. 24.

    Khadgi BB, Govindaraju A, Christensen SM. Completion of LINE integration involves an open ‘4-way’ branched DNA intermediate. Nucleic Acids Res. 2019;47:8708-8719.

    Not in our library10.1093/nar/gkz673

  25. 25.

    Kojima KK. Different integration site structures between L1 protein-mediated retrotransposition in cis and retrotransposition in trans. Mob. DNA. 2010;1:17.

    Not in our library10.1186/1759-8753-1-17

  26. 26.

    Fukuda S, et al. Cytoplasmic synthesis of endogenous Alu complementary DNA via reverse transcription and implications in age-related macular degeneration. Proc. Natl Acad. Sci. USA. 2021;118:e2022751118.

    Not in our library10.1073/pnas.2022751118

  27. 27.

    Thomas CA, et al. Modeling of TREX1-dependent autoimmune disease using human stem cells highlights L1 accumulation as a source of neuroinflammation. Cell Stem Cell. 2017;21:319-331.e318.

    Not in our library10.1016/j.stem.2017.07.009

  28. 28.

    Rajurkar M, et al. Reverse transcriptase inhibition disrupts repeat element life cycle in colorectal cancer. Cancer Discov. 2022;12:1462-1481.

    Not in our library10.1158/2159-8290.cd-21-1117

  29. 29.

    Benitez-Guijarro M, et al. RNase H2, mutated in Aicardi-Goutieres syndrome, promotes LINE-1 retrotransposition. EMBO J. 2018;37:e98506.

    Not in our library10.15252/embj.201798506

  30. 30.

    Stamos JL, Lentzsch AM, Lambowitz AM. Structure of a thermostable group II intron reverse transcriptase with template-primer and its functional and evolutionary implications. Mol. Cell. 2017;68:926-939.e924.

    Not in our library10.1016/j.molcel.2017.10.024

  31. 31.

    Pyle AM. Group II intron self-splicing. Annu. Rev. Biophys. 2016;45:183-205.

    Not in our library10.1146/annurev-biophys-062215-011149

  32. 32.

    Piskareva O, Schmatchenko V. DNA polymerization by the reverse transcriptase of the human L1 retrotransposon on its own template in vitro. FEBS Lett. 2006;580:661-668.

    Not in our library10.1016/j.febslet.2005.12.077

  33. 33.

    Dai L, Huang Q, Boeke JD. Effect of reverse transcriptase inhibitors on LINE-1 and Ty1 reverse transcriptase activities and on LINE-1 retrotransposition. BMC Biochem. 2011;12:18.

    Not in our library10.1186/1471-2091-12-18

  34. 34.

    Baldwin ET, et al. Human endogenous retrovirus-K (HERV-K) reverse transcriptase (RT) structure and biochemistry reveals remarkable similarities to HIV-1 RT and opportunities for HERV-K-specific inhibition. Proc. Natl Acad. Sci. USA. 2022;119:e2200260119.

    Not in our library10.1073/pnas.2200260119

  35. 35.

    Lentzsch AM, Stamos JL, Yao J, Russell R, Lambowitz AM. Structural basis for template switching by a group II intron-encoded non-LTR-retroelement reverse transcriptase. J. Biol. Chem. 2021;297:100971.

    Not in our library10.1016/j.jbc.2021.100971

  36. 36.

    Pimentel SC, Upton HE, Collins K. Separable structural requirements for cDNA synthesis, nontemplated extension, and template jumping by a non-LTR retroelement reverse transcriptase. J. Biol. Chem. 2022;298:101624.

    Not in our library10.1016/j.jbc.2022.101624

  37. 37.

    Christian CM, Sokolowski M, deHaro D, Kines KJ, Belancio VP. Involvement of conserved amino acids in the C-terminal region of LINE-1 ORF2p in retrotransposition. Genetics. 2017;205:1139-1149.

    Not in our library10.1534/genetics.116.191403

  38. 38.

    Adney EM, et al. Comprehensive scanning mutagenesis of human retrotransposon LINE-1 identifies motifs essential for function. Genetics. 2019;213:1401-1414.

    Not in our library10.1534/genetics.119.302601

  39. 39.

    Christian CM, deHaro D, Kines KJ, Sokolowski M, Belancio VP. Identification of L1 ORF2p sequence important to retrotransposition using Bipartile Alu retrotransposition (BAR). Nucleic Acids Res. 2016;44:4818-4834.

    Not in our library10.1093/nar/gkw277

  40. 40.

    Ruiz F, Arnold E. Evolving understanding of HIV-1 reverse transcriptase structure, function, inhibition, and resistance. Curr. Opin. Struct. Biol. 2020;61:113-123.

    Not in our library10.1016/j.sbi.2019.11.011

All 77 references

Cited by papers we hold 1

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.